Hepatology and Liver Transplant Medicine Unit, Flinders Medical Centre, Bedford Park, Australia; South Australian Liver Transplant Unit, Flinders Medical Centre, Bedford Park, Australia.
Liver Transpl. 2013 Oct;19(10):1119-24. doi: 10.1002/lt.23714.
Despite the widespread use of locoregional therapies [radiofrequency ablation and transarterial chemoembolization (TACE)], there is currently a lack of high-quality evidence supporting their use for hepatocellular carcinoma (HCC) in patients on the liver transplantation (LT) waiting list or requiring down-staging. Radiotherapy has rarely been used in this setting and has usually been in the form of more complex and less accessible techniques such as proton-beam and stereotactic body radiation therapy. Only 1 report describes the use of conventional 3-dimensional conformal external-beam radiotherapy (cEBRT) techniques as neoadjuvant or down-staging therapy for patients who are LT candidates. This report describes the use of cEBRT in a 52-year-old hepatitis C-positive man with cirrhosis. A 40-mm right lobe HCC was treated initially with TACE while he was on the waiting list. The lesion progressed beyond transplant criteria (76 mm). Conventional external-beam radiotherapy (EBRT) was used (54 Gy in 27 fractions) to down-stage the lesion. EBRT was well tolerated and resulted in a complete radiological response with no arterial enhancement of the lesion for a total of 16 months. Subsequent LT and a review of the explant demonstrated complete histological necrosis of the lesion. This report provides the first description of complete histological necrosis of HCC through the use of cEBRT techniques as down-staging/neoadjuvant therapy before LT. Because of its potential efficacy, accessibility, tolerability, noninvasive and outpatient nature, and ability to treat lesions adjacent to vessels and biliary structures, further trials examining the efficacy of cEBRT versus other neoadjuvant techniques are urgently required.
尽管局部区域治疗[射频消融和经动脉化疗栓塞(TACE)]广泛应用,但目前缺乏高质量证据支持其在肝移植(LT)等待名单上或需要降期的肝细胞癌(HCC)患者中使用。放射治疗在这种情况下很少使用,通常采用更复杂且难以获得的技术,如质子束和立体定向体放射治疗。只有 1 份报告描述了使用传统的 3 维适形外照射放射治疗(cEBRT)技术作为 LT 候选患者的新辅助或降期治疗。该报告描述了一名 52 岁丙型肝炎阳性、肝硬化患者使用 cEBRT 的情况。一名 40 毫米的右叶 HCC 在等待名单期间最初接受 TACE 治疗。该病变进展超出移植标准(76 毫米)。使用常规外照射放疗(EBRT)(54 Gy 分 27 次)使病变降级。EBRT 耐受性良好,导致病变完全放射学反应,无动脉增强,共 16 个月。随后进行 LT 并对标本进行检查,显示病变完全组织学坏死。该报告首次描述了通过使用 cEBRT 技术作为 LT 前降期/新辅助治疗,完全组织学坏死 HCC。由于其潜在疗效、可及性、耐受性、非侵入性和门诊性质,以及能够治疗紧邻血管和胆道结构的病变,迫切需要进一步的临床试验来检查 cEBRT 与其他新辅助技术的疗效。